Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled Trial [0.03%]
基于社区的药剂师领导的丙型肝炎诊断和快速管理（PHARM-C）：非盲IV期随机对照试验结果
Mia J Biondi,Camelia I Capraru,Ben Harper et al.
Mia J Biondi et al.
This was a nonblinded randomised controlled trial comparing pharmacist-led hepatitis C virus (HCV) treatment in the community, to tertiary care hepatology. Of 34 antibody-positive individuals, 28 completed a rapid HCV RNA test in the pharma...
Clinical Trial
Journal of viral hepatitis. 2026 Jan;33(1):e70109. DOI:10.1111/jvh.70109 2026
Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023 [0.03%]
巴基斯坦基层医疗卫生中心的去中心化丙肝管理模式：2022年8月至2023年6月的一个简化的整合护理模式
Sara Mazzilli,Muhammad K Aslam,Mubashir Ahmed et al.
Sara Mazzilli et al.
Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HC...
Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update [0.03%]
关于贝西奥特单药或联合治疗慢性丁型肝炎：2025年更新
Pietro Lampertico,Maria Paola Anolli,Katja Steppich et al.
Pietro Lampertico et al.
Chronic hepatitis Delta (CHD) represents the most aggressive form of viral hepatitis. In the latest estimates, published in 2024 by the Polaris Observatory, the overall prevalence of the hepatitis Delta virus (HDV) in Hepatitis B surface an...
Targeted Screening for Hepatitis B: Insights From Hong Kong and Implications for Endemic Regions [0.03%]
乙肝靶向筛查：香港的实践及其在乙型肝炎流行地区应用的启示
Mohamed El-Kassas,Maen Almattooq,Khalid M AlNaamani
Mohamed El-Kassas
Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross-Sectional Study [0.03%]
英格兰慢性乙肝病毒感染者的人口统计特征及其HBsAg分层：一项横断面研究
Myriam Drysdale,Iain A Gillespie,Dina Christensen et al.
Myriam Drysdale et al.
Characterisation of people with hepatitis B (PwHB) remains limited, particularly regarding treatment status, disease severity and biomarker profiles. Quantitative hepatitis B surface antigen (qHBsAg) is a key predictor of response to emergi...
Bridging the Gap: How Distance to Hospitals Limits HCV Treatment Initiation in France [0.03%]
Bridging the Gap：法国医院距离限制丙肝治疗的现状及应对措施
Fabienne Marcellin,Vincent di Beo,Philippe Sogni et al.
Fabienne Marcellin et al.
Hepatitis B Virus (HBV) Treatment Eligibility in the UK: Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines [0.03%]
英国乙型肝炎病毒(HBV)治疗适应证的变化对临床指南的影响:回顾性纵向队列数据
Cori Campbell,Tingyan Wang,Alexander J Stockdale et al.
Cori Campbell et al.
Nucleos/tide analogue (NA) drugs are used for long-term treatment of chronic hepatitis B virus (HBV) infection, with treatment eligibility criteria changing rapidly amidst globally evolving clinical guidelines. We aimed to quantify the pres...
Hepatitis B Knowledge, Attitudes and Mistrust in Western Medicine Among People of Filipino Ethnicity in Australia [0.03%]
澳大利亚菲律宾族人的乙肝知识、对西医不信任的态度调查
Robyn Horwitz,Loren Brener,Elise de Romas et al.
Robyn Horwitz et al.
Hepatitis B is highly prevalent among migrant communities from endemic regions, with an estimated 70% of Australians living with chronic hepatitis B having been born overseas. Research suggests that there are significant gaps in hepatitis B...
Human Herpesvirus 6 in Acute Liver Failure: Leading Role, Supporting Actor or Innocent Bystander? A Case Series, Narrative Review and Management Algorithm Proposal [0.03%]
人疱疹病毒6型与急性肝衰竭：主角、配角还是无辜旁观者？病例系列研究，叙述性综述及管理流程图建议
Andrés Conthe,Pablo Ramón Fueyo,Fernando Aguilera et al.
Andrés Conthe et al.
In recent years, an increasing number of acute liver failure (ALF) cases have been attributed to HHV-6, although its pathogenic role remains debated. In the absence of standardised diagnostic criteria, HHV-6 is likely underrecognized as a p...
Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long-Term Clinical Outcomes [0.03%]
识别真正的免疫耐受期慢性乙肝患者：长期临床结局带来的启示
Jung Hyun Kwon,Sung Won Lee,Hee-Yeon Kim et al.
Jung Hyun Kwon et al.
The long-term prognosis of immune tolerant (IT) phase patients remains unclear. This study aimed to identify true IT-phase patients with favourable outcomes and distinguish grey-zone IT patients. We retrospectively analysed 1064 chronic hep...